Till A Kämmerer1, Victor Palarie2, Eik Schiegnitz1, Valentin Topalo3, Andrea Schröter4, Bilal Al-Nawas1, Peer W Kämmerer5. 1. Department of Oral, Maxillofacial and Plastic Surgery, University Medical Center Mainz, Mainz, Germany. 2. Laboratory of Tissue Engineering, State University of Medicine and Pharmacy "N. Testemitanu", Chisinau, Moldova. 3. Clinic for Oral & Maxillofacial Surgery, State University of Medicine and Pharmacy "N. Testemitanu", Chisinau, Moldova. 4. DOT GmbH Medical Implant Solutions, Rostock, Germany. 5. Department of Oral, Maxillofacial and Plastic Surgery, University Medical Center Rostock, Rostock, Germany.
Abstract
BACKGROUND: Calcium phosphate (CaP) surface coatings may accelerate osseointegration and serve as a drug delivery system for mineral-binding biomolecules. In a pilot study, the impact of a commercially available, thin CaP coating on early osseous bone remodeling was compared with a modern, subtractive-treated rough surface (SLA-like) in an animal trial. METHODS: In 16 rabbits, 32 endosseous implants (CaP; n = 16, SLA-like; n = 16) were bilaterally inserted in the proximal tibia after randomization. After 2 and 4 weeks, bone-implant contact (BIC;%) in the cortical (cBIC) and the trabecular bone (sBIC) as well as volume of bone within the screw thread with the highest amount of new-formed bone (area;%) were analyzed. RESULTS: After 2 weeks, cBIC was significantly higher for CaP when compared with SLA-like (58 ± 7% versus 40.4 ± 18%; P = 0.021). sBIC for CaP was 14.7 ± 8% and for SLA-like 7.2 ± 7.8% (P = 0.081). For area, the mean volumes were 82.8 ± 10.8% for CaP and 73.6 ± 22% for SLA-like (P = 0.311). After 4 weeks, cBIC was 42.9 ± 13% for the CaP and 46.5 ± 29.1% for the SLA-like group (P = 0.775). An sBIC of 6.9 ± 9.3% was calculated for CaP and of 12.3 ± 4.8% for SLA-like (P = 0.202). The values for area were 62.3 ± 24.1% for CaP and 50.1 ± 25.9% for SLA-like (P = 0.379). CONCLUSIONS: The CaP coating has putative additional advantages in the early osseoconduction phases. It seems suitable for a feasible and clinical applicable bioactivation.
BACKGROUND:Calcium phosphate (CaP) surface coatings may accelerate osseointegration and serve as a drug delivery system for mineral-binding biomolecules. In a pilot study, the impact of a commercially available, thin CaP coating on early osseous bone remodeling was compared with a modern, subtractive-treated rough surface (SLA-like) in an animal trial. METHODS: In 16 rabbits, 32 endosseous implants (CaP; n = 16, SLA-like; n = 16) were bilaterally inserted in the proximal tibia after randomization. After 2 and 4 weeks, bone-implant contact (BIC;%) in the cortical (cBIC) and the trabecular bone (sBIC) as well as volume of bone within the screw thread with the highest amount of new-formed bone (area;%) were analyzed. RESULTS: After 2 weeks, cBIC was significantly higher for CaP when compared with SLA-like (58 ± 7% versus 40.4 ± 18%; P = 0.021). sBIC for CaP was 14.7 ± 8% and for SLA-like 7.2 ± 7.8% (P = 0.081). For area, the mean volumes were 82.8 ± 10.8% for CaP and 73.6 ± 22% for SLA-like (P = 0.311). After 4 weeks, cBIC was 42.9 ± 13% for the CaP and 46.5 ± 29.1% for the SLA-like group (P = 0.775). An sBIC of 6.9 ± 9.3% was calculated for CaP and of 12.3 ± 4.8% for SLA-like (P = 0.202). The values for area were 62.3 ± 24.1% for CaP and 50.1 ± 25.9% for SLA-like (P = 0.379). CONCLUSIONS: The CaP coating has putative additional advantages in the early osseoconduction phases. It seems suitable for a feasible and clinical applicable bioactivation.
Authors: Andreas Pabst; Ashraf Asran; Steffen Lüers; Markus Laub; Christopher Holfeld; Victor Palarie; Daniel G E Thiem; Philipp Becker; Amely Hartmann; Diana Heimes; Bilal Al-Nawas; Peer W Kämmerer Journal: Biomedicines Date: 2022-04-19
Authors: Peer W Kämmerer; Malte Scholz; Maria Baudisch; Jan Liese; Katharina Wegner; Bernhard Frerich; Hermann Lang Journal: Stem Cells Int Date: 2017-08-16 Impact factor: 5.443
Authors: S A Alkaabi; D S Natsir Kalla; G A Alsabri; A Fauzi; A Tajrin; W E G Müller; H C Schröder; X G Wang; T Forouzanfar; M N Helder; M Ruslin Journal: Trials Date: 2021-06-14 Impact factor: 2.279